Oncology Drug Access Delays in Spain: A Growing Concern
The waiting time for access to innovative oncology medications in Spain has reached 627 days, according to the latest Patients W.A.I.T. report by IQVIA, a global health science company. This marks an increase from the previous 613 days recorded in the earlier study, reflecting a growing challenge in ensuring timely access to life-saving treatments for cancer patients.
Key Findings from the Report
The Patients W.A.I.T. study, commissioned by the European Federation of Pharmaceutical Industries and Associations (EFPIA), analyzed data from 36 European countries. It evaluated 168 innovative cancer drugs approved between 2021 and 2024, with updates as of January 5, 2026.
In Spain, 73% of the 56 oncology drugs approved during this period were available to patients, translating to 41 medications. This contrasts sharply with Germany, which leads in availability at 91%. On a broader European scale, the average waiting time for oncology treatments rose to 655 days, up from 586 days in the prior report.
European Trends and Disparities
The report highlights significant disparities across the European Union. While countries like Germany, Austria, and Italy exceed 75% availability, others struggle with limited access. 49% of innovative drugs remain unavailable to European patients, with availability rates declining from 42% in 2019 to 28% in the current study.
The average time for drugs to become available across the EU27 increased to 597 days, up from 578 days. This trend underscores systemic challenges in aligning drug approvals with patient access, exacerbated by regulatory and financial barriers.
Implications for Patients and Healthcare Systems
Extended waiting times for oncology drugs can have severe consequences for patients, potentially impacting treatment outcomes and quality of life. The report emphasizes the need for streamlined processes to accelerate access to innovative therapies while maintaining safety standards.
Healthcare policymakers and stakeholders are urged to address these delays through collaborative efforts, including harmonizing regulatory frameworks and investing in healthcare infrastructure. The findings also call for greater transparency in drug approval timelines to better inform patients, and providers.
Looking Ahead
The Patients W.A.I.T. report serves as a critical benchmark for monitoring progress in drug accessibility. As the healthcare landscape evolves, continuous evaluation and adaptation of policies will be essential to ensure equitable access to oncology treatments across Europe.
Worth a look